{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
colchicine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Thiocolchicine is a colchicine-derivative used in the therapy of some diseases and extensively studied in the field of oncological research as antimitotic agent. It is tubulin polymerization and microtubule assembly inhibitor and axonal cytoskeleton modulator; apoptosis inducer. Thiocolchicine-dimers were shown to be potent topoisomerase I inhibitors. Thiocolchicine is a potential antitumor agent.
Trimethylcolchicinic acid (also known as deacetyl colchicine) was used for patients with advanced malignancies. However, these studies were discontinued. Expeiments on rat were shown, that trimethylcolchicinic acid was able to improve normal liver histology, ultrastructure, collagen content and biochemical markers of liver damage in spite of that trimethylcolchicinic acid, didn't bind tubulin.
Status:
Possibly Marketed Outside US
Source:
ANDA211519
(1961)
Source URL:
First approved in 1961
Source:
ANDA211519
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Colchiceine, a metabolite of colchicine, commonly used to treat gout, was studied as an effective compound in the model of liver damage.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Demecolcine, also called Colcemid, was isolated from the autumn crocus in 1950 and commercialized by Ciba. Initially, it was explored as a cancer drug due to its low toxicity. Demecolcine depolymerizes microtubules and limits microtubule formation (inactivates spindle fiber formation), thus arresting cells in metaphase and allowing cell harvest and karyotyping to be performed. Today, it is only used as a research tool mainly to overcome limitations of colchicine due to its very slow association and dissociation rate constants. It binds to tubulin at the same site as colchicine, but ~10-fold faster, and it also dissociates faster. Demecolcine main use has been to arrest cells in mitosis for cytogenetic analysis, though to our knowledge it offers no special advantages over other drugs in this application.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
